Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Prostatic Intraepithelial Neoplasia 1Male Urogenital Diseases 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Lycopene × Clear all
NCT01882985 2021-01-05

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

University of California, Irvine

Phase 2 Completed
14 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00450749 2019-12-18

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

NCT01443026 2019-11-19

The Effects of Lycopene on High Risk Prostatic Tissue

University of Illinois at Chicago

Phase 2 Completed
66 enrolled 8 charts
Genitourinary

Prostatic Neoplasms, Prostatic Intraepithelial Neoplasia, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡